Risk Factors Update Summary
- Addition of new approved products for sale: ZYNYZ, with exclusive licensees selling OLUMIANT for rheumatoid arthritis and atopic dermatitis.
- Labeling update for JAKAFI to include warnings of increased risk of major adverse cardiovascular events.
- Notice letter received regarding generic version of OPZELURA, challenging patents covering ruxolitinib phosphate cream.
- Expansion of international operations with office in China and evaluation of strategic relationships with various companies.
- Increased use of social media tools and new technology, including artificial intelligence software, for communication and work enhancement.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=879169&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.